Feeds:
Posts
Comments

Posts Tagged ‘Dendreon’

GSK and Pfizer join forces to create a new company focused on HIV. I really like the idea here – I think highly-focused companies can be much more nimble and effective.

Dendreon finally gets some good clinical news about experimental prostate cancer treatment Provenge.

B-I launches new unbranded website for TIA (mini-stroke) sufferers.

If there was any doubt as to who was taking over whom (Roche/Genetech), let’s put that to rest.

——

Subscribe to the Impactiviti blog via e-mail

Subscribe to the Impactiviti blog via RSS

Connect with Steve Woodruff

Read Full Post »

Just what we need – another takeover rumor! Is GSK interested in Allergan? Or, perhaps, is Allergan interested in its own acquisitions?

Hospira cutting its workforce by 10%.

Dendreon finds a new way to endanger Provenge. This is a head-scratcher…

PLUS – Pfizer grabs its new Oncology Business Unit head from Cephalon.

——

Subscribe to the Impactiviti blog via e-mail

Subscribe to the Impactiviti blog via RSS

Connect with Steve Woodruff

Read Full Post »

J&J announces leadership transition – Johnson & Johnson appointed Sheri McCoy, leader of its surgical care group, on Thursday worldwide chairman of its pharmaceuticals group, effective Jan. 1. McCoy will replace Christine Poon, whose departure from J&J was announced last month. Poon, who has also served as J&J’s board vice chairman, plans to step down in March…more

Teva and AZ in a tiff about Crestor patents.

FDA to Takeda on Alogliptin review: Sorry, understaffed! – Takeda Pharmaceutical Co, Japan’s biggest drugmaker, said on Friday that U.S. health authorities have not been able to complete a review of a key diabetes drug candidate on schedule due to lack of resources…more

AZ‘s PurplePill website continues to generate impressive traffic numbers.

1 in 4 teenage girls have received Gardasil – Whether this means Merck’s HPV vaccine is making great inroads is unclear, but Gardasil does appear to be on its way to becoming accepted, according to the first federal government study of vaccination rates for the controversial shot…more

Rituxan OK’d for cancer treatmentRheumatoid arthritis drug Rituxan helps to fight cancer, but now its makers can actually share that with the world…more

Watson gets approval for Rapaflo for BPH – Watson Pharmaceuticals, Inc., a leading specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has approved RAPAFLO(TM) (silodosin), the company’s new alpha blocker for the treatment of the signs and symptoms of BPH…more

Neurontin: the gaffe that keeps on taking – Pfizer Inc  tried to suppress medical studies that did not support the use of its epilepsy drug Neurontin, internal Pfizer documents submitted in a U.S. lawsuit against the company showed…more

St. John’s Wort for depressiondoes he or doesn’t he?

Drug samples under attack!

Eli Lilly buying up ImClone.

Dendreon’s Provenge has some tantalizing data, but still must wait – Amid the stock sell-off, a bright spot appears and, of all things, it turns out to be Dendreon, the controversial and much-maligned little company that continues to press ahead with its Provenge prostate cancer vaccine…more

Another university looks at banning pharma gifts – A university medical school task force recommends prohibiting faculty, medical residents and students from receiving gifts from drug and device makers, according to an unreleased report obtained by The Minnesota Daily, the university’s newspaper. Docs would also be required to disclose all relationships with a drugmaker before writing a prescription and create a website to report conflicts…more

King and Alpharma start talking – Are you surprised? After the usual posturing and harsh language, the two drugmakers have agreed to a confidentiality agreement, according to a filing with the US Securities and Exchange Commission…more

Who should get Avastin? Genetic tests may tellGenetic tests could in future show who will respond best to Genentech and Roche’s blockbuster cancer drug Avastin — a positive development for patients but not necessarily for sales…more

Spiriva: more not-so-great mixed results – Spiriva, marketed by Pfizer and Boehringer Ingelheim, offered no advantage over an inhaled placebo for moderate-to-very-severe chronic obstructive pulmonary disease, or COPD, researchers reported on Sunday…more On the other hand, Novartis has a promising new COPD candidate doing well in mid-stage trials.

Peter Rost whistleblower suit against Pfizer gains new traction.

Good results for Remicade in combo treatment – Crohn’s disease patients taking Johnson & Johnson’s (JNJ.N: Quote, Profile, Research, Stock Buzz) Remicade either alone or with azathioprine experienced steroid-free remission in significantly greater numbers than those taking azathioprine alone, according to results of a clinical trial…more

Reblog this post [with Zemanta]

Read Full Post »